The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 6,7 This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.6.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

JANUARY 17, 2021

Previously Rexgenero Ltd, a UK-based company pioneering the development of cell therapies to treat serious diseases such as cancer and chronic limb-threatening ischaemia (CLTI), the launch of Ixaka follows integration of its nanoparticle gene therapy business in France and a shareholder restructuring. A total of $15.4 A total of $15.4

Gene Therapy 40

Gene Therapy Gene In-Vivo Genetics 40

Drug Discovery World

OCTOBER 21, 2022

The advance could mean that future development of anti-cancer therapies won’t require the use of animal models. Triple-negative breast cancer cells can develop resistance to the chemotherapy drug doxorubicin. “The 3D bioprinted breast cancer tumours. 3D bioprinted breast cancer tumours. New target for hard-to-treat breast cancer.

In-Vivo 52

In-Vivo Research Drugs Engineer 52

The Pharma Data

JUNE 17, 2022

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). However, immunocompromised individuals still lack effective immunity against SARS-CoV-2 infection.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

pharmaphorum

JANUARY 17, 2023

Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution. The pandemic proved that mRNA technology could provide effective protection against infectious disease, at least in the case of COVID-19.

Vaccination 89

Vaccination Vaccine In-Vivo In-Vitro 89

Drug Discovery World

JULY 22, 2022

Immunotherapies have become more popular due to their ability to trigger and train the patient’s immune system to recognise and attack tumour cells, provide strong immune responses, and reduce the severity of adverse side effects generally associated with chemotherapies. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. Treatment vaccines : these boost the immune system responses to target cells. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . billion in 2020, according to the Alliance for Regenerative Medicine’s (ARM’s) Regenerative Medicine: Disrupting the Status Quo report.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

DECEMBER 15, 2022

Possible solutions: A new generation of gene editing tools is being developed to avoid double stranded breaks altogether and to be potentially less destructive than traditional nuclease systems. In vivo approaches involve delivering the gene editing components directly into the patient. In one example, Choi et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

NOVEMBER 8, 2023

On Day 1, Tuesday 14 November 2023, the tracks include: Display of biologics, antibody-based cancer therapies, safety and efficacy of bispecific antibodies, modulating the tumour microenvironment, optimisation and developability, and cell line and systems engineering.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

NOVEMBER 13, 2023

On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against membrane protein targets, engineering bispecific antibodies, next-generation immunotherapies, protein stability and formulation, and protein process development.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

JULY 8, 2021

Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. The FDA grants Priority Review to applications for medicines that offer significant advantages over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.(1) Reese, M.D.,

Allergies 52

Allergies Trials In-Vivo Medicine 52

Pharma Marketing Network

JANUARY 20, 2021

In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic. Regarding OWS’s support for vaccine development, Dr Slaoui noted that 5 of the 6 vaccines selected (from a total of 94 programs) are currently in phase 3 development or approved.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

Drug Discovery World

FEBRUARY 2, 2023

Bryan Oronsky , Chief Development Officer at EpicentRx, discucsses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. A late-stage clinical trial in head and neck cancer for the treatment of severe oral blistering or oral mucositis caused by radiation therapy is planned.

Manufacturing 52

Manufacturing Clinical Trials Clinical Trials Drugs 52

The Pharma Data

APRIL 27, 2021

General Medicines core assets grew 4.4%, while GBU sales were down 3.8%. Progress on implementation of the Corporate Social Responsibility strategy. Sanofi has become a member of the top five companies of the 2021 Access to Medicine index. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4%

Sales 52

Sales Vaccination Vaccine Medicine 52

The Pharma Data

OCTOBER 26, 2020

The purpose of this exploratory Phase 1b/2 trial was to evaluate the safety and efficacy of the combination of TG4001 and an immune checkpoint inhibitor in a heterogeneous group of patients with aggressive, recurrent and/or metastatic HPV16-positive cancers. An overall response rate of 23.5%

Vaccination 52

Vaccination Vaccine Trials Containment 52